Compare iShares MSCI Australia ETF (EWA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Novavax Inc — how do they compare? iShares MSCI Australia ETF trades at $28.71, while Novavax Inc trades at $8.27 (market cap $1.39B). The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| EWA | NVAX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.26 | $11.19 |
52-Week Low | $24.95 | $6.22 |
Market Cap | — | $1.39B |
Enterprise Value | — | $890.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.66, down 0.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $28, while resistance clusters near $29. The stock lacks disclosed financial ratios, and a dividend of $0.40 is scheduled for June 2026. Recent news highlights Australian economic factors and sector-specific developments influencing sentiment.
The outlook is mixed, with technical strength offset by limited fundamental visibility. Risks include reliance on Australian market conditions and macroeconomic headwinds. Investment appeal hinges on future financial disclosures and broader market trends.
Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.
The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
